Growth trend continues
As shown in the following graphic, specialty pharmaceuticals have the highest growth potential in long-standing manufacturing locations which are working to full capacity.
With the background of the strong increasing demand in the area of molecular imaging and the product diversity of the company, several licences have been granted to European competitors in 2009. In doing so, the licensee produces pharmaceuticals of IASON in regions which IASON cannot supply due to the short shelf-life of its own products, including the application of synthesis modules which were developed by ARGOS for the specific production of new innovative PET radiopharmaceuticals.
At the end of 2010, IASON achieved a further milestone in the area of quality management by being certified according to ISO 9001.